ENOV vs. ESTA, AVNS, SNN, SHC, FOLD, IDYA, SGRY, XENE, TMDX, and CRNX
Should you be buying Enovis stock or one of its competitors? The main competitors of Enovis include Establishment Labs (ESTA), Avanos Medical (AVNS), Smith & Nephew (SNN), Sotera Health (SHC), Amicus Therapeutics (FOLD), IDEAYA Biosciences (IDYA), Surgery Partners (SGRY), Xenon Pharmaceuticals (XENE), TransMedics Group (TMDX), and Crinetics Pharmaceuticals (CRNX). These companies are all part of the "medical" sector.
Enovis (NYSE:ENOV) and Establishment Labs (NASDAQ:ESTA) are both medical companies, but which is the superior business? We will compare the two businesses based on the strength of their dividends, media sentiment, analyst recommendations, earnings, risk, valuation, community ranking, profitability and institutional ownership.
98.5% of Enovis shares are owned by institutional investors. Comparatively, 72.9% of Establishment Labs shares are owned by institutional investors. 2.4% of Enovis shares are owned by insiders. Comparatively, 11.4% of Establishment Labs shares are owned by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock is poised for long-term growth.
Enovis has higher revenue and earnings than Establishment Labs. Enovis is trading at a lower price-to-earnings ratio than Establishment Labs, indicating that it is currently the more affordable of the two stocks.
Establishment Labs received 89 more outperform votes than Enovis when rated by MarketBeat users. Likewise, 62.22% of users gave Establishment Labs an outperform vote while only 58.97% of users gave Enovis an outperform vote.
In the previous week, Establishment Labs had 2 more articles in the media than Enovis. MarketBeat recorded 6 mentions for Establishment Labs and 4 mentions for Enovis. Establishment Labs' average media sentiment score of 0.56 beat Enovis' score of 0.44 indicating that Establishment Labs is being referred to more favorably in the news media.
Enovis has a beta of 1.97, indicating that its stock price is 97% more volatile than the S&P 500. Comparatively, Establishment Labs has a beta of 1.24, indicating that its stock price is 24% more volatile than the S&P 500.
Enovis has a net margin of -1.95% compared to Establishment Labs' net margin of -47.53%. Enovis' return on equity of 3.84% beat Establishment Labs' return on equity.
Enovis presently has a consensus price target of $75.43, indicating a potential upside of 36.97%. Establishment Labs has a consensus price target of $55.00, indicating a potential upside of 13.31%. Given Enovis' higher probable upside, equities research analysts clearly believe Enovis is more favorable than Establishment Labs.
Summary
Enovis beats Establishment Labs on 10 of the 17 factors compared between the two stocks.
Get Enovis News Delivered to You Automatically
Sign up to receive the latest news and ratings for ENOV and its competitors with MarketBeat's FREE daily newsletter.
This chart shows the number of new MarketBeat users adding ENOV and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
This chart shows the average media sentiment of NYSE and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Related Companies and Tools
